Dogwood Therapeutics DWTX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $21.87M+519% | $3.53M+104% | $1.73M-78.6% | $8.07M-25.3% | ||
| $6.1M-29.8% | $8.7M+134% | $3.72M-12.4% | $4.25M-12.4% | ||
| $27.97M+129% | $12.23M+124% | $5.45M-55.8% | $12.32M-21.3% | ||
| -$27.97M-129% | -$12.23M-124% | -$5.45M+55.8% | -$12.32M+21.3% | ||
| $96.94K+205% | -$92.19K-161% | $150.9K— | —— | ||
| -$6.13M-4,881% | -$122.98K-181% | $150.9K+124% | $67.48K+121% | ||
| -$34.04M-176% | -$12.35M-133% | -$5.3M+56.8% | -$12.25M+23.3% | ||
| -$34.26M-177% | -$12.35M-133% | -$5.3M+56.8% | -$12.25M+23.3% | ||
| —— | -$12.45-289% | -$3.20-167% | -$1.20+37.5% | ||
| -$27.97M-129% | -$12.23M-124% | -$5.45M+55.8% | -$12.32M+21.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dogwood Therapeutics profitable?
- Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
- What is Dogwood Therapeutics's earnings per share?
- Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
- Where does Dogwood Therapeutics's income statement data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.